Pfizer booster shows 95.6% efficacy in Phase 3 trial, companies say
In September, the US Food and Drug Administration authorized a booster dose of the Pfizer/BioNtech coronavirus vaccine for emergency use in adults 65 and older. |!| Chattanooga
In September, the US Food and Drug Administration authorized a booster dose of the Pfizer/BioNtech coronavirus vaccine for emergency use in adults 65 and older. |!| Chattanooga